SAVSU Technologies to Supply evo® Cold Chain Technologies to AveXis
Temperature Sensitive Gene Therapy Protected by Cloud-Connected Smart Shipper and evo.is Cloud App for Real Time Distribution Visibility and Management On November 5, 2018, BioLife’s JV partner SAVSU Technologies, a leading developer and supplier of precision cloud-connected thermal shipping containers and the most advanced cold chain visibility platform, announced that it is supplying its evo Smart […]
Biopreservation Reagents Continue to Grow
The number of applications for BioLife Solutions’ biopreservation reagents continues to grow, and we are pleased to highlight these newest citations: Habiel, D., Espindola, M., Coelho, A., & Hogaboam, C. Modeling Idiopathic Pulmonary Fibrosis in Humanized SCID Mice. The American Journal of Pathology 2018 Apr; 188(4): 891-903. doi: 10.1016/j.ajpath.2017.12.020 Habiel et. al. provided detailed methods for the creation […]
New CryoStor Citations and Our Growing Evidence Library
BioLife maintains an EVIDENCE PAGE on our corporate website with links to presentations, journal articles, abstracts and posters. We currently have over 365 citations and counting! Evidence is searchable by titles and keywords; and provides a tremendous resource for researchers and clinicians looking for relevant information on cell type, variant of optimized biopreservation media (for example: CS5 or CS10), […]
BioLife Biopreservation Evidence Resources + New Citations
BioLife maintains an evidence page on our corporate website at biolifesolutions.com with links to presentations, journal articles, abstracts and posters citing the biopreservation efficacy of CryoStor and HypoThermosol. These citation “evidence” pieces total over 345 strong and is constantly growing! Individual evidence citations (journal articles, abstracts, and posters citing our products) are searchable by title and keyword and provides […]
Delivering a Cost Effective, Practical and Robust Cell Therapy Supply Chain
FDA approvals for Novartis’ Kymriah™ and Kite’s Yescarta™ in 2017 ushered in a new era of medical treatments using cell and gene therapies. Transporting these high value, unique, and often irreplaceable autologous cells from point of collection, to processing center, and back to the patient for administration calls for a paradigm change to the traditional […]
Casdin Capital to Become Shareholder in BioLife Solutions – Investment Firm to Purchase Shares from Existing Holder
On April 9, 2018 BioLife Solutions Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, (“BioLife” or the “Company”), announced that Casdin Capital LLC, (“Casdin”) a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company’s second largest […]
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading supplier of pre-formulated, clinical grade cell and tissue hypothermic storage and cryopreservation freeze media (“BioLife”), announced on July 13th 2017 that Kolon Life Science, TissueGene’s exclusive licensee for Asia, including Korea, has received marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis from the Korea Ministry of Food […]